To develop a radiomics nomogram based on radiomic features derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) combined with clinical-imaging characteristics in predicting the CD8+Tumor-infiltrating lymphocytes (TILs) levels in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). The gene discussed is ERBB2; the disease is breast cancer.